Argent BioPharma Management

Management criteria checks 3/4

Argent BioPharma's CEO is Roby Zomer, appointed in Feb 2016, has a tenure of 8.75 years. total yearly compensation is A$417.06K, comprised of 92.8% salary and 7.2% bonuses, including company stock and options. directly owns 17.12% of the company’s shares, worth A$2.23M. The average tenure of the management team and the board of directors is 2.1 years and 3.9 years respectively.

Key information

Roby Zomer

Chief executive officer

AU$417.1k

Total compensation

CEO salary percentage	92.8%
CEO tenure	8.8yrs
CEO ownership	17.1%
Management average tenure	2.1yrs
Board average tenure	3.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Roby Zomer's remuneration changed compared to Argent BioPharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	AU$417k	AU$387k	-AU$18m
Mar 31 2024	n/a	n/a	-AU$17m
Dec 31 2023	n/a	n/a	-AU$17m
Sep 30 2023	n/a	n/a	-AU$19m
Jun 30 2023	AU$354k	AU$354k	-AU$21m
Mar 31 2023	n/a	n/a	-AU$22m
Dec 31 2022	n/a	n/a	-AU$23m
Sep 30 2022	n/a	n/a	-AU$22m
Jun 30 2022	AU$629k	AU$422k	-AU$20m
Mar 31 2022	n/a	n/a	-AU$19m
Dec 31 2021	n/a	n/a	-AU$18m
Sep 30 2021	n/a	n/a	-AU$17m
Jun 30 2021	AU$481k	AU$281k	-AU$16m
Dec 31 2020	n/a	n/a	-AU$13m
Sep 30 2020	n/a	n/a	-AU$16m
Jun 30 2020	AU$440k	AU$290k	-AU$19m
Dec 31 2019	n/a	n/a	-AU$18m
Sep 30 2019	n/a	n/a	-AU$14m
Jun 30 2019	AU$495k	AU$330k	-AU$11m
Dec 31 2018	n/a	n/a	-AU$7m
Sep 30 2018	n/a	n/a	-AU$7m
Jun 30 2018	AU$498k	AU$334k	-AU$8m

Compensation vs Market: Roby's total compensation ($USD269.94K) is about average for companies of similar size in the Australian market ($USD298.48K).

Compensation vs Earnings: Roby's compensation has increased whilst the company is unprofitable.

CEO

Roby Zomer (44 yo)

8.8yrs

Tenure

AU$417,064

Compensation

Mr. Roby Reuven Zomer is a Co-Founder of Argent BioPharma Limited (formerly known as MGC Pharmaceuticals Limited) and served as its Interim Chief Financial Officer since April 2022 until April 2022. Mr. Zo...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Roby Zomer	Co-Founder	8.8yrs	AU$417.06k	17.12% A$ 2.2m
Igor Bluvstein	Chief Financial Officer	less than a year	no data	no data
Yifat Steuer	Deputy CEO & COO	2.1yrs	no data	2.06% A$ 268.1k
Shachar Shimony	Group General Counsel	no data	no data	no data
Masa Oblak	People Manager	no data	no data	no data
Amir Polak	Chief Pharmaceutical Development Officer	no data	no data	1.09% A$ 142.2k
Sabina Suljakovic	Chief Quality and Commercial Officer	4.2yrs	no data	no data
Nadya Lisovoder	Chief Medical Officer	no data	no data	no data
Sasha Friedman	Deputy CEO	no data	no data	no data
Yair Tal	Chief Information Security Officer	no data	no data	no data
Rowan Harland	Company Secretary	1.7yrs	no data	no data
Ana Oblak	Group Financial Controller	no data	no data	no data

2.1yrs

Average Tenure

Experienced Management: RGT's management team is considered experienced (2.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Roby Zomer	Co-Founder	8.8yrs	AU$417.06k	17.12% A$ 2.2m
Ross Grant Walker	Chairman of Strategic Advisory Board	no data	AU$32.00k	no data
Uri Kramer	Member of Strategic Advisory Board	8.3yrs	no data	no data
Layton Mills	Independent Non-Executive Director	1.4yrs	AU$61.92k	no data
Wendyl D'Souza	Member of Medical Advisory Board	6.3yrs	no data	no data
Daniel Robinson	Non-Executive Director	less than a year	AU$41.92k	no data
Shlomo Sadoun	Member of Advisory Board	less than a year	no data	no data

3.9yrs

Average Tenure

Experienced Board: RGT's board of directors are considered experienced (3.9 years average tenure).

Argent BioPharma Management

Management criteria checks 3/4

Key information

Recent management updates

Co-Founder recently bought AU$1.6m worth of stock

Less than half of directors are independent

Argent BioPharma Limited, Annual General Meeting, Nov 28, 2024

Less than half of directors are independent

Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer

Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board

Recent updates

Argent BioPharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.

Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.2 million.

Co-Founder recently bought AU$1.6m worth of stock

Full year 2024 earnings released: AU$0.47 loss per share (vs AU$7.07 loss in FY 2023)

Less than half of directors are independent

Argent BioPharma Limited, Annual General Meeting, Nov 28, 2024

Argent BioPharma Provides Update on Proposed Delisting from the Australian Securities Exchange

Argent BioPharma Provides Update on Proposed Delisting from the Australian Securities Exchange

Full year 2024 earnings released: AU$0.47 loss per share (vs AU$7.07 loss in FY 2023)

Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New major risk - Market cap size

Less than half of directors are independent

Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer

Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board

Less than half of directors are independent

Less than half of directors are independent

New major risk - Market cap size

Less than half of directors are independent

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.74 million.

MGC Pharmaceuticals Limited's Product Artemic Receives FDA Approval in Saudi Arabia

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Board Changes

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 12.4 million.

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New major risk - Shareholder dilution

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New minor risk - Financial data availability

MGC Pharmaceuticals Limited Announces Positive Pre-Clinical Trial Results on CimetrA®

MGC Pharmaceuticals Limited Announces Executive Changes

MGC Pharmaceuticals Limited Announces Resignation of Arron Canicais, Joint Company Secretary

New major risk - Shareholder dilution

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of £0.65 million.

New major risk - Market cap size

MGC Pharmaceuticals Limited Announces Appointment of Layton Mills as Non-Executive Director

MGC Pharmaceuticals Limited Announces Board Changes, Effective 1 June 2023

First half 2023 earnings released: AU$0.004 loss per share (vs AU$0.003 loss in 1H 2022)

MGC Pharmaceuticals Limited Announces Change of CFO

MGC Pharmaceuticals Ltd Completes the Pre-Clinical Rodent Studies on Cimetratm

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Resignation of Evan Hayes as Director

MGC Pharmaceuticals Limited Announces Completion of CimetrA Efficacy Pre-Clinical Trial

Mgc Pharmaceuticals Ltd Announces the Results of the Open Label Clinical Study, a White Label Version of ArtemiCTM Support

MGC Pharmaceuticals Limited Provides an Update on Its Operations

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 24, 2022

Mgc Pharmaceuticals Limited Announces Board Changes

Full year 2022 earnings released: AU$0.008 loss per share (vs AU$0.008 loss in FY 2021)

MGC Pharmaceuticals Successfully Developed Herbal-Inspired Products for Treatment of Long Covid and Covid-19

MGC Pharmaceuticals Limited Announces Interim Results from the Data Collected from the Initial 16 Patients Participating in the CimetrA Dose Finding Study

MGC Pharmaceuticals Limited, Annual General Meeting, Oct 05, 2022

Full year 2022 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2021)

MGC Pharmaceuticals Ltd Provides the Following Results from A Recently Completed Randomised, Double Blind, Placebo Controlled Study Investigating the Effect of MGC's Pharma's Epilepsy Treatment, Cannepil®, on Vehicle Driving Performance, Sedation and Mood (Trial)

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10 million in funding from Mercer Street Capital Partners, LLC

Mgc Pharmaceuticals Ltd Announces Appointment of Mr. Robert Clements as Chief Commercial Officer

MGC Pharmaceuticals Limited Announces Long COVID Study Results for Artemic Support

MGC Pharmaceuticals Limited Receives Approval Granted for the Dose Finding Study of CimetrA on Patients Diagnosed With Covid-19

MGC Pharmaceuticals Limited Announces the Launch of ZAM- Medical Data App in Collaboration with Caba Tech

MGC Pharmaceuticals Limited Announces CimetrA Pre-Clinical Trial Progress Report

Mgc Pharmaceuticals Limited Announces Cimetra Clinical Trial Progress

MGC Pharmaceuticals Ltd Has Completes Successful In-Vitro Preclinical Research Study into the Use of Cannabinoids to Treat Glioblastoma Multiforme Cells, A Fast-Growing and Aggressive Form of Brain Cancer

Mgc Pharmaceuticals Ltd to Provide Details of the Results of Its Phase II Clinical Trial into the Effect of Its Proprietary Investigational Medicinal Product, CogniCann

MGC Pharmaceuticals Ltd Patent Application forCannEpil®Drug Delivery System Patent granted by European IP Office

Mgc Pharmaceuticals Limited Announces Appointment of Angela-Marie Graham as Its New London Based Chief Financial Officer

MGC Pharmaceuticals Ltd Announces Patent Application for CimetrATM Approve by European IP Office

MGC Pharmaceuticals Limited Announces Executive Changes

MGC Pharmaceuticals Ltd Receives an Import Approval Permit for the Importation of ArtemiCTM Rescue into India

Swiss PharmaCan Ag Announces Start of Clinical Trial with Glow LifeTech and MGC Pharmaceuticals to Confirm Treatment Potential of Artemic Support in Long Covid Patients

MGC Pharmaceuticals Limited announced that it has received £5.5 million in funding

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10.3 million in funding